IFRX Stock Risk & Deep Value Analysis
InflaRx NV
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on IFRX
We analyzed InflaRx NV using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran IFRX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
📈IFRX Performance Overview3yr weekly
Unlock IFRX Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
IFRX Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
About InflaRx NV (IFRX)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
small
Market Cap
$81.30M
IFRX Deep Value Analysis
Compare IFRX to Similar Stocks
See how InflaRx NV stacks up against related companies in our head-to-head analysis.
IFRX Red Flags & Warning Signs
Premium- ⚠
Failure to secure adequate or favorable financing terms, leading to severe dilution or insolvency
- ⚠
Continued slow commercial uptake of Gohibic, missing sales targets
- ⚠
Adverse clinical trial results for pipeline candidates or new indications
- ⚠
Increased competitive pressure from new or existing treatments for ANCA-associated vasculitis
Unlock IFRX Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
IFRX Financial Health Metrics
Market Cap
$81.30M
IFRX Competitive Moat Analysis
PremiumMoat Rating
Narrow
Moat Trend
Stable but vulnerable
Moat Sources
1 Identified
The moat is primarily derived from intellectual property and regulatory exclusivity. Its durability hinges on successful commercialization, further clinical development, and maintaining differentiation against new competitive entrants or alternative therapies. If commercial execution fails, the regulatory and IP moat becomes less valuable.
IFRX Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
IFRX Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated early-mid May 2026), focusing on Gohibic sales and cash position
- •Financing announcement (equity, debt, or partnership) - critical and imminent
- •Updates on Gohibic commercialization efforts and market penetration in the EU
Medium-Term (6-18 months)
- •Sustained acceleration in Gohibic sales and revenue growth in European markets
- •Potential strategic partnerships for global commercialization or additional indications
- •Progress on vilobelimab's development pipeline or expansion into new therapeutic areas
Long-Term (18+ months)
- •Establishment of Gohibic as a leading treatment for ANCA-associated vasculitis globally
- •Expansion of vilobelimab's approved indications, broadening the TAM
- •Potential acquisition by a larger pharmaceutical company seeking to enhance its rare disease portfolio
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
IFRX Bull Case: What Could Go Right
- ✓
Significant acceleration in Gohibic sales figures (quarter-over-quarter growth)
- ✓
Announcement of a favorable financing deal or strategic partnership that significantly extends the cash runway
- ✓
Positive clinical data for vilobelimab in new indications
- ✓
Failure to secure financing, continued slow sales, or highly dilutive equity offerings
Bull Case Analysis
See what could go right with Premium
Never miss a move on IFRX
Create a free account to set price alerts and get notified on Telegram when IFRX hits your targets.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for InflaRx NV (IFRX)?
As of March 12, 2026, InflaRx NV has a DVR Score of 4.0 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of InflaRx NV?
InflaRx NV's market capitalization is approximately $81.3M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does InflaRx NV use?
IFRX is the ticker symbol for InflaRx NV. The company trades on the NMS.
What is the risk level for IFRX stock?
Our analysis rates InflaRx NV's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the IFRX DVR analysis updated?
Our AI-powered analysis of InflaRx NV is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 12, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.